Jade Biosciences (JBIO) Stock News, Jun-Oct 2025

Jade Biosciences (Nasdaq: JBIO) announced JADE201, an investigational half-life extended, afucosylated monoclonal antibody targeting BAFF receptor for autoimmune diseases.

Preclinical non-human primate data showed dose-dependent BAFF-R occupancy, sustained B‑cell depletion after a single subcutaneous dose, and ~2x half-life versus ianalumab. JADE201 combines afucosylation for enhanced ADCC and an Fc mutation to extend systemic exposure while preserving activity.

A randomized, placebo-controlled, single-ascending-dose first-in-human trial in rheumatoid arthritis is expected to begin in H1 2026. The company will host a conference call and webcast on Oct 7, 2025 at 8:00 a.m. ET.

Jade Biosciences (Nasdaq: JBIO) announced a private placement expected to raise approximately $135 million in gross proceeds via a PIPE financing, subject to customary closing conditions with an expected close on or about October 8, 2025. The transaction sells 13,368,164 shares at $9.14 and 1,402,092 pre-funded warrants at $9.1399 each (exercise price $0.0001).

After issuance, there will be about 67.4 million shares and equivalents outstanding. The company said net proceeds plus existing cash are expected to fund operations into 1H 2028. Placement agents and a registration rights agreement were disclosed.

Jade Biosciences (NASDAQ:JBIO) has initiated dosing in its Phase 1 clinical trial of JADE101, a novel anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN). The trial marks a significant milestone in developing a potential best-in-class treatment for this autoimmune kidney disease.

The Phase 1 study is designed as a randomized, double-blind, placebo-controlled trial evaluating single ascending subcutaneous doses in healthy volunteers. The company expects to report interim data in H1 2026, which will help determine optimal dosing strategies for future IgAN patient studies.

JADE101 has demonstrated promising preclinical results, including femtomolar binding affinity to APRIL and sustained IgA reductions in non-human primates, suggesting potential for convenient eight-week or longer dosing intervals.

Jade Biosciences (Nasdaq: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in three upcoming healthcare conferences in September 2025.

The company will participate in the Cantor Global Healthcare Conference (September 3-5), the Stifel Virtual Immunology and Inflammation Forum (September 15-16), and the 11th Annual World Medical Innovation Forum (September 15-17). Management will conduct fireside chats and participate in a panel discussion on immunology, while also hosting one-on-one investor meetings.

Webcasts of the Cantor and Stifel fireside chats will be available on Jade's website with 90-day replay access.

Jade Biosciences (NASDAQ:JBIO) reported Q2 2025 financial results and corporate updates, highlighting progress in its autoimmune disease therapy development. The company's lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrated promising preclinical results with ultra-high binding affinity and sustained IgA suppression. A Phase 1 trial is expected to begin in Q3 2025.

Financial highlights include $220.9 million in cash and equivalents, providing runway through 2027. Q2 2025 saw R&D expenses of $22.5 million and G&A expenses of $5.2 million, with a net loss of $32.1 million. The company also appointed Brad Dahms as CFO and continues development of JADE201, targeting multiple systemic autoimmune diseases, with clinical entry planned for H1 2026.

Jade Biosciences (Nasdaq: JBIO), a biotechnology company developing therapies for autoimmune diseases, has announced its participation in two upcoming investor conferences.

CEO Tom Frohlich and CSO Dr. Andrew King will present at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 p.m. ET, and the 2025 Stifel Biotech Summer Summit on August 13, 2025, at 7:30 a.m. ET. The management team will also host one-on-one investor meetings during both events.

Jade Biosciences (NASDAQ:JBIO), a biotechnology company developing therapies for autoimmune diseases, has appointed Brad Dahms as Chief Financial Officer. Dahms brings significant experience from his previous roles as CFO and CBO at IDRx, where he orchestrated its sale to GSK for up to $1.15 billion, and as CFO of Theseus Pharmaceuticals and Selecta Biosciences.

The appointment comes as Jade prepares to advance its lead candidate JADE101 into clinical trials for IgA nephropathy this year. The company aims to leverage Dahms' expertise in financial operations, business development, and capital markets following its recent Nasdaq listing and private financing round.

Jade Biosciences (NASDAQ: JBIO) presented promising preclinical data for JADE101, its anti-APRIL monoclonal antibody for IgA nephropathy treatment, at the 62nd ERA Congress. The data revealed JADE101's superior profile with femtomolar APRIL binding affinity (50 fM), 750-fold higher than competitor sibeprenlimab. In non-human primates, JADE101 demonstrated a 27-day half-life, nearly 4x longer than sibeprenlimab, with sustained IgA suppression lasting over 100 days after a single dose. The drug showed high subcutaneous bioavailability and was designed to avoid immune complex formation risks. At just 4 mg/kg, JADE101 achieved better results than 30 mg/kg of sibeprenlimab. The company plans to initiate human trials in H2 2025, with interim data expected in H1 2026.

Jade Biosciences (NASDAQ: JBIO) announced it will present new preclinical data for JADE101, its anti-APRIL monoclonal antibody for IgA nephropathy (IgAN) treatment, at the 62nd European Renal Association Congress in Vienna (June 4-7, 2025). The presentation titled 'Discovery and Characterization of JADE101' will be delivered by Erin Filbert, Executive Director of Research and Translational Medicine, during the Focused Oral Session on June 6, 2025. The company will host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the presented data, with registration available on the company's website.